Ripertamab for generalized myasthenia gravis
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This study tests a new medicine called ripertamab for people with generalized myasthenia gravis (gMG), a condition that causes muscle weakness. The medicine aims to reduce the immune system's attack on muscles, which may help improve daily activities and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with generalized myasthenia gravis (gMG), meaning muscle weakness affects more than just your eyes.
- You have a positive blood test for certain antibodies related to myasthenia gravis (AChR, MuSK, or LRP4).
- Your daily symptoms are at least moderately severe (a score of 6 or more on the MG-ADL scale), with less than half of those symptoms being eye-related.
- You have not had certain treatments recently (like rituximab, immunosuppressants, plasma exchange, or IVIG) within specific timeframes.
- You have not had a thymectomy (surgery to remove the thymus gland) in the past year and do not plan to have one during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called empasiprubart for people with generalized myasthenia gravis (gMG) who have a certain antibody (AChR-Ab). It is given as a monthly IV infusion (into a vein) and aims to improve muscle weakness and daily functioning.
This trial tests a new drug called Ripertamab for people with neuromyelitis optica spectrum disorder (NMOSD), a condition that causes inflammation in the optic nerves and spinal cord. The drug aims to reduce relapses (flare-ups) of symptoms. It may be an option if you've had recent relapses despite current treatment.
This study adds a new drug called empasiprubart to the existing treatment efgartigimod for people with generalized myasthenia gravis (gMG) who have antibodies against acetylcholine receptors (AChR-Ab) and have only partially responded to efgartigimod. The goal is to see if the combination improves daily living more than efgartigimod alone.
This trial tests a new medicine called ripertamab for children and young adults with nephrotic syndrome that keeps coming back or requires steroids. The goal is to see if it helps prevent relapses with fewer side effects.
This study tests a new drug called aritinercept to see if it can help people with generalized myasthenia gravis (a condition where muscles weaken over time). Researchers believe this drug may reduce the immune system activity that causes muscle weakness.
This trial tests whether ravulizumab, a medication that blocks part of the immune system, can improve muscle weakness and fatigue in people with generalized myasthenia gravis (gMG). The study focuses on Chinese adults who have moderate-to-severe MG symptoms despite current treatments.
Hear when a new Myasthenia Gravis (MG) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.